Labo EuromedisFRA:61R +0.42%61 Current Ratio is 3.36 as of Dec. 2025, which is at its 10-year median of 3.36. GuruFocus rates FRA:61R with a GF Score™ of 61/100 and a GF Value™ of €4.37. The stock has 6 warning signs investors should review. Among 118 Medical Distribution companies, Labo Euromedis ranks better than 91.53% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Labo Euromedis's current ratio for the quarter that ended in Dec. 2025 was 3.36.
Labo Euromedis has a current ratio of 3.36. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Labo Euromedis's Current Ratio or its related term are showing as below:
FRA:61R'
s Current Ratio Range Over the Past 10 Years
Min: 1.4 Med: 3.36 Max: 5.43
Current: 3.36
During the past 13 years, Labo Euromedis's highest Current Ratio was 5.43. The lowest was 1.40. And the median was 3.36.
FRA:61R's Current Ratio is ranked better than 91.53% of 118
companies
in the Medical Distribution industry
Industry Median: 1.395
vs FRA:61R: 3.36
Labo Euromedis (FRA:61R) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Labo Euromedis Current Ratio Related Terms
Labo Euromedis Current Ratio Historical Data
* Premium members only.
The historical data trend for Labo Euromedis's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:61R vs MCK, CAH, COR: Current Ratio Comparison
For the Medical Distribution subindustry, Labo Euromedis's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Labo Euromedis Current Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Labo Euromedis's Current Ratio distribution charts can be found below:
* The bar in red indicates where Labo Euromedis's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Labo Euromedis (FRA:61R) has a Current Ratio of 3.36 as of Dec. 2025. This is near median its historical median of 3.36. Over the past decade, Labo Euromedis' Current Ratio has ranged from 1.40 to 5.43. According to the industry distribution chart, Labo Euromedis ranks #10 out of 118 companies in the Medical Distribution industry, placing it in the top 8.5%.
Is Labo Euromedis' Current Ratio too high?
Labo Euromedis' current Current Ratio of 3.36 is near median its 10-year median of 3.36. Over the past 10 years, this metric has ranged from a low of 1.40 to a high of 5.43. The Medical Distribution industry median Current Ratio is 1.40. Labo Euromedis' value of 3.36 is 140.9% above this industry median. Based on the distribution chart, Labo Euromedis ranks #10 out of 118 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Labo Euromedis has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does Labo Euromedis' Current Ratio compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Labo Euromedis ranks #10 out of 118 companies for Current Ratio. This places Labo Euromedis in the top 9% of its industry — outperforming the majority of peers. The industry median Current Ratio is 1.40. Labo Euromedis' value of 3.36 is 140.9% above this benchmark. Historically, Labo Euromedis' own Current Ratio has ranged from 1.40 to 5.43 over the past decade. While the company's 10-year median is 3.36 vs. the industry median of 1.40, Labo Euromedis has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Distribution company?
The median Current Ratio among Medical Distribution companies is 1.40, based on 118 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Labo Euromedis's current Current Ratio of 3.36 is 140.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Current Ratio is 1.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Labo Euromedis's current Current Ratio is 3.36, which is near median its own 10-year median of 3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Labo Euromedis stock overvalued right now?
Labo Euromedis (FRA:61R) has a current Current Ratio of 3.36. The stock's GF Value™ is €4.37, compared to a current price of €4.76 — trading 8.9% above its estimated fair value. The current Current Ratio is 3.36, which is near median its 10-year median of 3.36 and 140.9% above the Medical Distribution industry median of 1.40. Labo Euromedis' overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Labo Euromedis (FRA:61R), the current Current Ratio is 3.36 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Labo Euromedis (FRA:61R) Overvalued in 2026?
Based on GuruFocus' analysis, Labo Euromedis stock appears to be overvalued.
The current stock price of €4.76 is trading 8.9% above its estimated GF Value™ of €4.37.
Key valuation signals for FRA:61R:
Current Ratio: 3.36 (near median its 10-year median of 3.36)
GF Value™: €4.37 vs. price of €4.76 (8.9% above fair value)
Industry Position: 140.9% above the Medical Distribution median (#10 of 118)
No single metric tells the full story. See the FRA:61R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Labo Euromedis is engaged in medical devices. It is engaged in the design, manufacture, rental and export of medical and surgical equipment and products.
61GF Score
Get the complete analysis for FRA:61R
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:61R has been successfully added to your 
